U.S. Health Secretary Robert F. Kennedy Jr. on Tuesday added two rare genetic disorders, Duchenne Muscular Dystrophy and ...
For nearly a decade, Solid has been a staunch supporter and a steering committee member of Parent Project Muscular Dystrophy’s (PPMD) committee dedicated to implementing newborn screening for Duchenne ...
Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...
Today, the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchenne) to the Recommended Uniform Screening Panel (RUSP), the national list of conditions ...
Health secretary Robert F. Kennedy Jr. on Tuesday added two deadly rare diseases, Duchenne muscular dystrophy and ...
This announcement follows a bipartisan letter that Senator Collins and a group of nine members of Congress sent last month to ...
Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.
Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET –SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.
Dyne is readying a competitor to Sarepta’s Exondys 51. Elsewhere, a pair of obesity drugs showed promise and Kymera’s protein-degrading medicine displayed “biologic-like or better efficacy,” according ...
Since NS Pharma launched its Duchenne muscular dystrophy (DMD) drug Viltepso (viltolarsen) in 2020, sales have steadily trended upward, with the company expecting the treatment to generate 20,100 ...
Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to disease-related loss of muscle and movement, adverse effects of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback